| 0.1313 0.001 (0.92%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.16 | 1-year : | 0.17 |
| Resists | First : | 0.13 | Second : | 0.14 |
| Pivot price | 0.13  |
|||
| Supports | First : | 0.12 | Second : | 0.1 |
| MAs | MA(5) : | 0.12 |
MA(20) : | 0.13 |
| MA(100) : | 0.14 |
MA(250) : | 0.17 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.4 |
D(3) : | 14.9 |
| RSI | RSI(14): 45.9 |
|||
| 52-week | High : | 0.24 | Low : | 0.11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ZOM ] has closed above bottom band by 31.6%. Bollinger Bands are 35.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.13 - 0.14 | 0.14 - 0.14 |
| Low: | 0.13 - 0.13 | 0.13 - 0.13 |
| Close: | 0.13 - 0.13 | 0.13 - 0.13 |
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Mon, 01 Apr 2024
Zomedica Achieves Record Revenue and Strong Growth - TipRanks.com - TipRanks
Wed, 20 Mar 2024
Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday ... - Yahoo Finance
Wed, 13 Mar 2024
Zomedica Provides NYSE American Listing Update - Yahoo Finance
Tue, 12 Mar 2024
Should You Buy Zomedica Corp (ZOM) Stock After it Is Lower By 7.14% in a Week? - InvestorsObserver
Thu, 08 Feb 2024
Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences - Yahoo Finance
Tue, 06 Feb 2024
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 980 (M) |
| Shares Float | 964 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 8.5 (%) |
| Shares Short | 63,430 (K) |
| Shares Short P.Month | 62,890 (K) |
| EPS | -0.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.27 |
| Profit Margin | -62.3 % |
| Operating Margin | -93.8 % |
| Return on Assets (ttm) | -5.7 % |
| Return on Equity (ttm) | -5.7 % |
| Qtrly Rev. Growth | 32.9 % |
| Gross Profit (p.s.) | 0.01 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -6.57 |
| PEG Ratio | 0 |
| Price to Book value | 0.48 |
| Price to Sales | 5.35 |
| Price to Cash Flow | -9.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|